Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer.
Celus W, Oliveira AI, Rivis S, Van Acker HH, Landeloos E, Serneels J, Cafarello ST, Van Herck Y, Mastrantonio R, Köhler A, Garg AD, Flamand V, Tamagnone L, Marine JC, Di Matteo M, Costa BM, Bechter O, Mazzone M. Celus W, et al. Among authors: bechter o. Cancer Immunol Res. 2022 Jan;10(1):126-141. doi: 10.1158/2326-6066.CIR-21-0061. Epub 2021 Nov 23. Cancer Immunol Res. 2022. PMID: 34815265 Free PMC article.
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Prince HM, et al. Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7. Lancet. 2017. PMID: 28600132
Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial.
Eisterer W, De Vries A, Öfner D, Rabl H, Koplmüller R, Greil R, Tschmelitsch J, Schmid R, Kapp K, Lukas P, Sedlmayer F, Höfler G, Gnant M, Thaler J; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Eisterer W, et al. Anticancer Res. 2014 Nov;34(11):6767-73. Anticancer Res. 2014. PMID: 25368289 Clinical Trial.
Toward Minimal Residual Disease-Directed Therapy in Melanoma.
Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, Karras P, Brown D, Chang YH, Debiec-Rychter M, Adriaens C, Radaelli E, Wolter P, Bechter O, Dummer R, Levesque M, Piris A, Frederick DT, Boland G, Flaherty KT, van den Oord J, Voet T, Aerts S, Lund AW, Marine JC. Rambow F, et al. Among authors: bechter o. Cell. 2018 Aug 9;174(4):843-855.e19. doi: 10.1016/j.cell.2018.06.025. Epub 2018 Jul 12. Cell. 2018. PMID: 30017245 Free article.
A Multi-Omics Analysis of Metastatic Melanoma Identifies a Germinal Center-Like Tumor Microenvironment in HLA-DR-Positive Tumor Areas.
Gadeyne L, Van Herck Y, Milli G, Atak ZK, Bolognesi MM, Wouters J, Marcelis L, Minia A, Pliaka V, Roznac J, Alexopoulos LG, Cattoretti G, Bechter O, Oord JVD, De Smet F, Antoranz A, Bosisio FM. Gadeyne L, et al. Among authors: bechter o. Front Oncol. 2021 Mar 25;11:636057. doi: 10.3389/fonc.2021.636057. eCollection 2021. Front Oncol. 2021. PMID: 33842341 Free PMC article.
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma.
Marin-Bejar O, Rogiers A, Dewaele M, Femel J, Karras P, Pozniak J, Bervoets G, Van Raemdonck N, Pedri D, Swings T, Demeulemeester J, Borght SV, Lehnert S, Bosisio F, van den Oord JJ, Bempt IV, Lambrechts D, Voet T, Bechter O, Rizos H, Levesque MP, Leucci E, Lund AW, Rambow F, Marine JC. Marin-Bejar O, et al. Among authors: bechter o. Cancer Cell. 2021 Aug 9;39(8):1135-1149.e8. doi: 10.1016/j.ccell.2021.05.015. Epub 2021 Jun 17. Cancer Cell. 2021. PMID: 34143978 Free article.
Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma.
Vendramin R, Katopodi V, Cinque S, Konnova A, Knezevic Z, Adnane S, Verheyden Y, Karras P, Demesmaeker E, Bosisio FM, Kucera L, Rozman J, Gladwyn-Ng I, Rizzotto L, Dassi E, Millevoi S, Bechter O, Marine JC, Leucci E. Vendramin R, et al. Among authors: bechter o. J Exp Med. 2021 Sep 6;218(9):e20210571. doi: 10.1084/jem.20210571. Epub 2021 Jul 21. J Exp Med. 2021. PMID: 34287642 Free PMC article.
94 results